Will the FDA provide a clear regulatory pathway for ANKTIVA in NSCLC by December 31, 2026?
Current Prediction
Why This Question Matters
US NSCLC represents the largest potential expansion market for ANKTIVA. The Regulatory Reader noted discussions planned for 2026 but no formal pathway established. FDA clarity on NSCLC would materially de-risk the multi-indication thesis. Absence of progress would narrow the growth narrative to bladder cancer only.
Prediction Distribution
Individual Predictions(9 runs)
Management mentioned planned discussions with FDA on accelerated approval for NSCLC in 2026, but no formal pathway exists. NSCLC is a highly competitive indication with established checkpoint inhibitors (Keytruda, Opdivo). FDA may require substantial comparative data. Saudi Arabia approval does not guarantee US pathway.
The FDA's engagement with ANKTIVA (requesting QUILT 2.005 interim) suggests willingness to consider the product. However, NSCLC is a different therapeutic area with different standards. The question broadly includes meeting minutes, which are more achievable than full submission acceptance. ~38%.
The question includes FDA meeting minutes as resolution criteria, which is less demanding than actual approval pathway. If the company meets with FDA and discusses NSCLC, published minutes would resolve YES. Given management stated 2026 plans, a meeting is plausible. The question is whether it results in a 'clear pathway' as specified.
The broad question scope (IND acceptance, sNDA, meeting minutes) makes YES more achievable. ANKTIVA in combination with checkpoint inhibitors for NSCLC has international approvals, providing regulatory precedent. FDA engagement in 2026 is plausible. But 'clear pathway' is subjective and may not be met by a preliminary meeting.
FDA regulatory pathways for new indications take time. Even with planned discussions, a 'clear pathway' by year-end 2026 requires the FDA to be receptive and the data package to be compelling. Given the competitive NSCLC landscape and existing checkpoint inhibitor approvals, FDA may not see urgency.
Regulatory discussions are planned but outcomes are unpredictable. The RTF experience on papillary bladder cancer demonstrates that FDA engagement does not guarantee positive outcomes. ~38%.
Management plans discussions but FDA pathway for new indication is uncertain. NSCLC is crowded. International approvals help but don't guarantee US. ~38%.
Regulatory timelines are unpredictable. A clear FDA pathway by year-end 2026 requires favorable FDA reception and strong data package. Below 50% probability.
Saudi Arabia approval provides data package. FDA may accept based on international data plus supplemental US data. 40% probability given management plans and international precedent.
Resolution Criteria
Resolves YES if ImmunityBio publicly discloses FDA acceptance of an IND, sNDA, BLA submission, or published meeting minutes confirming a clear pathway (accelerated approval, breakthrough therapy designation, etc.) for ANKTIVA in NSCLC by December 31, 2026.
Resolution Source
ImmunityBio press releases, 8-K filings, or FDA meeting minutes
Source Trigger
US FDA pathway decision for NSCLC indication
Full multi-lens equity analysis